Medicines beyond barriers

medicines beyond barriersG2B

At Gate2Brain, we have found the key to unlocking the gate to the brain . We have developed a unique shuttle technology to cross the blood-brain barrier. A technology based on a set of peptides to allow the different therapeutic agents to reach the brain in a non-invasive form.

Our first target is pediatric high grades gliomas which is a group of non-curable and fast acting CNS disorders. Gate2Brain’s technology can be applied to other molecules and to other brain diseases. Gate2Brain holds the potential to treat some of the most devastating human diseases.

We are working to bring this technology to the market and go beyond barriers.

 

 

/by
You might also like
Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck
‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer
Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care Gate2Brain at MIT Pitch Day at University of Cambridge
Paidhos Gate2Brain wants to deliver drugs to the brain to combat intact barrier brain tumors, such as DIPG
EITHealth Catapult 2022eithealth Gate2Brain semifinalist of EITHealth’s Catapult 2022
Gate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series, a @Biocat initiative co-organized by the Delegation of the Government of Catalonia in Switzerland, The aim of the meeting is to put the best projects - from companies and/or research organizations - in contact with investors, business angels, venture capitalists and leading Swiss companies. Gate2Brain will be attending The Investment Readiness Series
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJD Nadia Calviño, First Vice President of the Government visits Gate2Brain
G2B receives funding to accelerate its transfer to the market and society
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

Gate2Brain semifinalist of EITHealth’s Catapult 2022 EITHealth Catapult 2022eithealth Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care Gate2Brain at MIT Pitch Day at University of Cambridge